News Breaks |
|
|
| November 12, 2012 |
| 12:00 EDT |  | CLVS | Clovis Oncology falls 36%
Clovis Oncology is down 36%, or $7.74, to $13.75 |
|
|
News For CLVS From The Last 14 Days Check below for free stories on CLVS the last two weeks. |
|
|
| May 16, 2013 |
| 07:39 EDT |  | CLVS | Clovis Oncology says data to be presented at ASCO annual meeting
Clovis Oncology announced that three abstracts highlighting results from three Phase I studies of the company’s two lead compounds will be presented at the American Society of Clinical Oncology, ASCO, Annual Meeting 2013 in Chicago. Data contained in the published abstracts was current as of the submission deadline of February 5, 2013. Data to be presented in the poster sessions will include data from the trials as of early May, the company said. |
|
| May 15, 2013 |
| 15:15 EDT | | CLVS | Clovis Oncology lung cancer treatment designated for orphan drug status
 Subscribe for More Information |
|
| May 7, 2013 |
| 14:58 EDT |  | CLVS | Clovis Oncology price target raised to $45 from $33 at JPMorgan
Subscribe for More Information |
|
| 07:07 EDT |  | CLVS | Clovis Oncology increases FY13 cash burn guidance to $60M-$65M
Subscribe for More Information |
|
| 07:05 EDT | | CLVS | Clovis Oncology reports Q1 EPS (60c), consensus (60c)
Subscribe for More Information |
|
|
|
|
|
